Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:01 PM
Ignite Modification Date:
2025-12-24 @ 5:01 PM
NCT ID:
NCT05008250
Eligibility Criteria:
Inclusion Criteria:
* Lown PVC grade, II-IVA;
* in patients with coronary heart disease and comorbid PVC or non-organic heart disease, the PVC frequency was 3000-30000 times/24 h;
* New York Heart Association grade, I or II;
* ejection fraction, ≥45%;
* written informed consent to participate in the trial.
Exclusion Criteria:
* presence of bradyarrhythmia (\<50 beats/min), including sinus syndrome and atrioventricular block (second or third degree atrioventricular block);
* presence of persistent ventricular tachycardia, non-persistent ventricular tachycardia, and/or persistent atrial fibrillation;
* presence of severe PVC requiring treatment with other antiarrhythmic drugs; -presence of drug-induced, electrolyte-induced, or acid-base-induced arrhythmia;
* presence of uncontrolled or severe hypertension (e.g., grade ≥3 hypertension);
* presence of uncontrolled diabetes; presence of alanine aminotransferase or aspartate aminotransferase level ≥1.5-fold above the upper limit of normal, urea nitrogen level ≥1.2-fold above the upper limit of normal, and/or blood creatinine above the upper limit of normal;
* presence of severe respiratory dysfunction or asthma;
* presence of primary hematopoietic diseases, other systemic diseases (e.g., hyperthyroidism), poor peripheral circulation perfusion, severe peripheral vascular diseases, and/or PVC with unknown etiology;
* presence of allergic constitution, mental disorder, alcoholism, and/or smoking habit;
* pregnancy or lactation;
* ongoing β-blocker treatment or contraindications to β-blocker treatment; -participation in other clinical trials within the prior 3 months;
* and other reasons for lack of suitability to participate in this study, as determined by the investigators.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT05008250
Study Brief:
Protocol Section:
NCT05008250